Distributor Partners

Please select …..

Vascular Access Procedural Solutions

Prevention of CIED Infection

 

Choose TauroPace to reduce Cardiovascular Implantable Electronic
Device-related infections in your department.

Get in Touch

Click here to read Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection, the full clinical study published in Oct 2023

The Challenge: CIED Infection Rising

 
The incidence of infection following implantation of cardiac implantable electronic devices (CIEDs) is increasing at a faster rate than that of device implantation.
Between 1993 and 2008, there was a 96% increase in the implantation of CIEDs. This coincided with a 210% increase in CIED infections.1
22-56% 2,3 of patients are considered to be at increased risk for CIED infection.
 

Preventing CIED Infections

 
TauroPace™ is a simple and effective way to reduce the risk of CIED infections. 4.
It is used to irrigate the surgical site, generator and leads..
It is clinically proven that:.
  • TauroPace™ reduces acute CIED infection risk in patients by up to 100%. 4
  • TauroPace™ enhances wound healing. 5
  • NO antibiotics, NO resistance. 6
The active ingredient within TauroPace™ is Taurolidine, which kills more than 500 types of bacteria and fungi 7 (including MRSA and VRE). Taurolidine is not an antibiotic and therefore avoids antibiotic resistance concerns. It quickly degrades to taurine, cardon dioxide and water when it enters the body.
 

Proven Results

 
A study published in October 2023 8 demonstrates that TauroPace™ is effective in preventing CIED infections:
  • Between 2017 and 2022, more than 1,300 patients undergoing at least one invasive CIED procedure were included.
  • TauroPace™ was used during 654 procedures on 631 patients.
  • 3% hydrogen peroxide (H2O2) was used during 551 procedures on 532 patients.
  • The acute CIED infection rate was 0.0% after adjunct TauroPace™ use and 1.09% after adjunct H2O2 use (over a 3-month period).
  • After total follow-up (15 months), CIED infection rate was 0.46% with TauroPace™ vs. 1.63% with H2O2.
These findings confirm the antimicrobial efficacy of taurolidine, the main active ingredient of TauroPace™: It kills a broad range of bacteria and fungi (incl. MRSA and VRSA), without generating bacterial resistance.
   
TauroPace™ H2O2 p-value
Number of Procedures 654 551
Number of Infections 0 6
Infection Rate 0.00% 1.09% <0.0075

Preventing CIED Infections Webinar Series:

Dr. Benito Baldauf MD, Consultant Cardiologist

 
 
 
 
 

1. Greenspon, A.J., et al., 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol, 2011. 58(10): p. 1001-6.

2. Mittal S et al. (2014) Heart Rhythm 11(4):595-601.

3. Eby E et al (2018) EP Europace. (s1):i106

4. Henke J, et al. (2022) European Journal of Arrhythmia & Electrophysiology.2022;8.

5. Wu L et al. (2021) Ann Transl Med. 2021;9;1010.

6. Radakovic S, et al. (2020) Antibiotics.2020;9:166

7. Torres-Viera, C., et al. (2000) Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis. Antimicrobial Agents and Chemotherapy. 44 (6): 1720–1724.

8. Borov et al. Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. EP Europace 2023. DOI: 10.1093/europace/euad306